Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
Carl J. Fichtenbaum(Cancer Research And Biostatistics), Steven Grinspoon(Massachusetts General Hospital), Heather J. Ribaudo(Cancer Research And Biostatistics), Sue Siminski(Frontier Science & Technology Research Foundation, Inc.), Edgar T. Overton(University of Alabama at Birmingham), Breno Santos(Hospital Nossa Senhora da Conceição), Craig A. Sponseller, Udo Hoffmann(Duke Medical Center), Yvetot Joseph(Gheskio Centers), Janet Lo(Harvard University), Jorge Leon-Cruz(Harvard University), Pamela S. Douglas(Duke University), Patrice Desvigne‐Nickens(National Heart Lung and Blood Institute), Kathleen Melbourne(Gilead Sciences (United States)), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Gerald S. Bloomfield, Estebán Martínez(Instituto de Salud Carlos III), Emma M. Kileel(Boston University), Judith S. Currier(University of California, Los Angeles), Kathleen V. Fitch(Harvard University), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Markella V. Zanni(Harvard University), Nagalingeswaran Kumarasamy(University of North Carolina at Chapel Hill), Marije Van Schalkwyk
Cited by 0
Related Papers
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
|Circulation|2012|2.4k
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
|New England Journal of Medicine|2012|2.3k